SupremeCourt

  • Subscribe to our RSS feed.
  • Twitter
  • StumbleUpon
  • Reddit
  • Facebook
  • Digg

Friday, June 28, 2013

Negotiating licenses between patent holders and generic producers: the Medicines Patent Pool

Posted on 7:36 AM by Unknown
The Medicines Patent Pool (MPP), backed by the United Nations, is a mechanism that has been formed with the intention of increasing access to HIV medicines in the developing world by increasing their affordability. The MPP negotiates licenses between patent holders and generic producers to make and sell HIV medicines at affordable prices to those who need it. An analysis of the concept of patent pools can be found here and here.  

The latest is the license negotiated by the MPP between the patent holder, Gilead Sciences and given to Shilpa Medicare, a Karnataka based generic producer to produce five key HIV medicines for sale in over 100 countries. The five HIV medicines for which the license is given are tenofovir, emtricitabine, cobicistat, elvitegravir and a combination of the four known as “the Quad”. 

Although, the purpose of the license is to provide these medicines to the needy at affordable prices, MPP makes no commitment about the price and the sale price of the drugs is as set by the market. From the market price of these medicines, a royalty of 3-5 per cent will be paid by Shilpa Medicare to the patent holder, Gilead Sciences depending on the medicine. It is interesting to note that Gilead Sciences was the first company to enter into an agreement with the MPP. Swaraj's post on the same is available here.

Shilpa Medicare is the sixth license holder of drug patents held by Gilead Sciences, through an agreement negotiated via MPP. The five other generic producers who tapped into the MPP to obtain licenses of Gilead Sciences are Aurobindo, Shasun, Laurus, Hetero and Emcure. Aurobindo, additionally holds another set of license of  pediatric HIV medicine, which was licensed to MPP by ViiV Healthcare. (ViiV Healthcare's colloboration with MPP is covered here.) This enables Aurobindo, a generic producer to produce medicines patented by Gilead Sciences and ViiV Healthcare, enabling greater access to needy people at affordable prices. This also provides Aurobindo an opportunity to produce combination drugs using the drugs patented by Gilead Sciences and ViiV Healthcare, which is generally impossible as the patents are owned by different companies. Such combination techniques, facilitated by MPP are an important and much more effective part of HIV treatment, as patients find it easier to take one pill that combines different drugs as opposed to the same drugs separately. This opinion finds support within the medical community, including organisations such as Doctors Without Borders.

The MPP acts as an intermediary between the patent holders and the generic producers. The participation of the patent holders in MPP's pool is voluntary and is mainly composed of large drug makers. Generic producers who express an interest to tap into the patent pool are assessed on various criteria including quality. The generic producers are usually required to obtain approval from regulatory authorities such as the US FDA or the WHO pre-qualification programme to tap into the patent pool. There is also a license management process which ensures through mechanisms such as quarterly reviews that the MPP licenses actually result in impact. However, questions have been raised about the licensing agreement, an excellent analysis of which is available here.

This is a welcome measure for the people of the developing world who are, many a time, denied access to life saving HIV medicine mainly because of its expense. As MPP works through a platform of voluntary participation, there has rightly been a call for increased participation by companies that hold patents for HIV drugs through MPP, not only because this leads to increased access through greater affordability but also provides for effective treatment by making the possibility of combination therapy between drugs patented by different companies possible.






Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Posted in AIDS/HIV, Gopika, Patent | No comments
Newer Post Older Post Home

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Popular Posts

  • IPAB on Payyannur Ring
    [*S lightly long post] Background: The Intellectual Property Appellate Board (“ IPAB ”), in its recent order in SubhashJewellery v. Payyan...
  • Satyajit Ray's sketches and copyright controversies
    A copyright row appears to have started between the Satyajit Ray Society and the Delhi Art Gallery, that is organising a countrywide exhibit...
  • Ghost Post: Samsung v. Apple Presidential Enforcement Veto
    SpicyIP subscribers recently received a short blurb from Shamnad on this FT article regarding the hypocrisy of stamping 'national inter...
  • Dorling Kindersley v. Sanguine Technical Publishers
    A recent Delhi High Court order passed on 21 January, 2013  with respect to copyright licensing has come to our notice. An analysis of the j...
  • SpicyIP Tidbit: ALCS August Distribution
    In the UK, the Authors' Licensing and Collecting Society is an organization run and owned by writers that collects money due to its mem...
  • Delhi HC rejects the "Hot News" Doctrine: A Summary
    The applicability of the Hot News doctrine was rejected recently in a landmark ruling delivered by Justice Bhat of the Delhi HC. This post i...
  • IP Research Assistant position at IIT, Madras
    Feroz Ali Khader, MHRD IP Chair at the Indian Institute of Technology (IIT) Madras, is looking for research assistants to work on various is...
  • Thalappakatti biryani trademark row
    The southern district of Dindigal in Tamil Nadu occupies a special place in the hearts of biryani lovers. In the late 1950s, one Nagasamy N...
  • SpicyIP Tidbit: GI for Pedana Kalamkari Art Form
    Image from here Recently, as The Hindu reports , Pedana Kalamkari art form received GI protection. Members of Vegetable Dye Hand Block Kalam...
  • Loss of an IP Leader: RIP Prof Daruwalla
    Most in the Indian IP firmament may have heard of the doleful demise of one of our IP leaders, Mr. Tehemtan Nasserwanji Daruwalla. He was an...

Categories

  • 126 (1)
  • 3(d) (4)
  • 3(f) (1)
  • 3(i) (1)
  • 3(k) (2)
  • Academic Writing (1)
  • access (10)
  • access to food (1)
  • access to health (3)
  • AIA (1)
  • AIDS/HIV (3)
  • Antitrust (2)
  • Bajaj v LML (1)
  • Basmati Row (2)
  • Biological Diversity (5)
  • Biologics (2)
  • biopiracy (4)
  • biotech (7)
  • Bollywood (25)
  • Broadcasters Rights (5)
  • Budget (1)
  • business method patent (2)
  • Call for papers (2)
  • Cipla (2)
  • Comparative Advertising (4)
  • Competition law (8)
  • Compulsory Licensing (27)
  • condonation of delay (1)
  • Conference (4)
  • Constitution (12)
  • Contracts (1)
  • Controller's decisions (8)
  • Copyright (112)
  • Copyright Amendment Bill 2010 (23)
  • copyright board (4)
  • Copyright Exceptions (6)
  • copyright office (1)
  • Copyright Rules (2013) (5)
  • Copyright Societies (9)
  • Counterfeiting (1)
  • creativity (1)
  • Cross Retaliation (1)
  • csir (4)
  • d (1)
  • D.U. Photocopy Case (16)
  • Darjeeling Tea (3)
  • Data Exclusivity (2)
  • Database (1)
  • DCGI (2)
  • decompilation (2)
  • defamation (9)
  • Designs (3)
  • Designs Act (3)
  • Differential Pricing (2)
  • Dilution (1)
  • Disabilities (3)
  • Disability (2)
  • DMCA (2)
  • Doha Declaration (1)
  • Domain Names (2)
  • Draft Policy of the Indian Government (2)
  • DRM (1)
  • Drug Regulation (7)
  • education (12)
  • Enercon (1)
  • Enforcement (1)
  • EU (2)
  • ex parte (2)
  • exhaustion (3)
  • Exhaustion of Rights (2)
  • Fair Dealing (8)
  • Fair Use (11)
  • Federal Circuit (1)
  • Fees (3)
  • FICCI (7)
  • FRAND (2)
  • free trade agreement (3)
  • FTA (3)
  • G.I. Registry (4)
  • gene sequences (3)
  • Generic medicine (4)
  • Geographical Indication (14)
  • Gilead (1)
  • Glenmark (5)
  • Gopika (34)
  • Guest post (11)
  • guidelines (1)
  • GWU-CII (1)
  • Herceptin (1)
  • hot news (3)
  • ICANN (1)
  • incremental innovation (1)
  • independence (1)
  • india (5)
  • Indian Government (1)
  • Indian patent litigation (27)
  • Indian Pharma (35)
  • Injunction (10)
  • Innovation (7)
  • INTA (1)
  • Intermediaries (10)
  • internet (11)
  • Internet Access Providers (IAPs) (5)
  • Internet Censorship (7)
  • IP scholarship (3)
  • IP aware (4)
  • IP Course (3)
  • IP Education (1)
  • IP Policy (11)
  • IP update (4)
  • ip writing competition (1)
  • IPAB (34)
  • ipchair (1)
  • IPO (1)
  • IPRS (5)
  • IT Act (1)
  • Journal (2)
  • judicial independence (3)
  • Jurisdiction (1)
  • Kruttika (4)
  • Legal Education (3)
  • Legal Research Tools (1)
  • Legal Scholarship (2)
  • library (2)
  • Licensing (7)
  • Madhulika (20)
  • mathematical methods (1)
  • Media law (3)
  • medical method (1)
  • Merck (4)
  • mhrd ip chair (1)
  • Microsoft (3)
  • Middle Path (1)
  • Moral Rights (2)
  • Movies (18)
  • musical work (2)
  • nanotechnology (1)
  • Natco (3)
  • natco defamation suit (5)
  • natco vs bayer (4)
  • need for transparency (1)
  • Novartis (8)
  • Novartis patent case in India (11)
  • NPEs (2)
  • nujs (1)
  • NUJS Conference (2)
  • Obituary (1)
  • obviousness (7)
  • Off-Topic (2)
  • online course (4)
  • Open Access (6)
  • Open Source (2)
  • Opposition (3)
  • Parallel Imports (4)
  • Parliament (1)
  • passing off (5)
  • Patent (52)
  • Patent act (10)
  • patent agent (5)
  • patent agent exam (9)
  • patent agent exam qualifications (3)
  • patent infringement (5)
  • Patent Licensing (2)
  • Patent litigation (2)
  • Patent Office (19)
  • patent pool (3)
  • Patent Prosecution (7)
  • Patent rules (2)
  • Patent Strategies (8)
  • Patents (9)
  • pegasus (1)
  • Personality Rights (1)
  • Pfizer (1)
  • Pharma (18)
  • Piracy (5)
  • plagiarism (3)
  • Plant Variety Protection (2)
  • post grant (1)
  • Prashant (2)
  • Preventive Detention (1)
  • Price Control (6)
  • prior publication (1)
  • Privacy (3)
  • Prizes (1)
  • public health (3)
  • Public Interest (4)
  • Publicity Rights (4)
  • Publishing (3)
  • radio (2)
  • Rajiv (18)
  • Rectification Petition (2)
  • Rejection (1)
  • research (3)
  • reverse engineering (2)
  • revocation (4)
  • rip (1)
  • Roche (2)
  • Roche vs Cipla (1)
  • Royalty (2)
  • RTI (2)
  • Scholarship (4)
  • section 16 (1)
  • Section 3(d) (7)
  • section 8 (6)
  • shamnad (11)
  • Shan Kohli (4)
  • Shouvik Kumar Guha (30)
  • Smartphones/Tablets (2)
  • Social Innovation (1)
  • Software (10)
  • software enforcement (3)
  • software patent (3)
  • Special 301 Report (1)
  • Spicy Tidbits (6)
  • spicyip (1)
  • SpicyIP Accolades (1)
  • SpicyIP Announcements (9)
  • SpicyIP Case (1)
  • SpicyIP Cases (3)
  • spicyip commiseration (1)
  • SpicyIP Events (11)
  • SpicyIP Fellowship (5)
  • SpicyIP Guest Series (22)
  • SpicyIP Interview (2)
  • SpicyIP Jobs (4)
  • SpicyIP Jobs/General (2)
  • SpicyIP Review (1)
  • SpicyIP Tidbits (11)
  • SpicyIP Weekly Review (27)
  • Statutory Licensing (1)
  • STI Policy 2013 (4)
  • Sugen (3)
  • Supreme Court of India (5)
  • Swaraj (19)
  • Tarnishment (1)
  • Technology (6)
  • Technology Transfer (5)
  • TKDL (5)
  • TPP (1)
  • trade (4)
  • Trade Secret Protection (1)
  • Trademark (59)
  • Trademark dilution (1)
  • Trademark Registry (9)
  • Traditional Knowledge (7)
  • Transparency (5)
  • treaty (1)
  • trial (1)
  • tribunals (2)
  • TRIPS (11)
  • UK (3)
  • unfair competition (5)
  • UNFCCC (1)
  • Universities Research and Innovation Bill (2)
  • US (1)
  • US Patent Reform (1)
  • US Supreme Court (3)
  • viva (3)
  • WIPO (5)
  • Working a Patent (2)
  • Workshop (4)
  • writ (1)
  • WTO (1)

Blog Archive

  • ▼  2013 (364)
    • ►  September (13)
    • ►  August (41)
    • ►  July (36)
    • ▼  June (36)
      • SpicyIP Weekly Review (June 2013, Week 5)
      • SpicyIP Tidbit: Update on Om Shanti Om Copyright D...
      • Guest Post: The legality of 'reverse payments' in ...
      • Internet Censorship: Is Blocking Porn Possible?
      • Delhi High court grants ex-parte injunction order ...
      • Negotiating licenses between patent holders and ge...
      • Om Shanti Om: Copyright Dispute
      • A quick look at Venus & PPL’s challenge to copyrig...
      • Internet Censorship: Gagging Mouthshut.com
      • Part II: Pfizer's testimony leads the way as US pr...
      • Part I: Pfizer's testimony leads the way as US pre...
      • Agreement reached on Treaty for the Visually Impai...
      • Guest Post: Kerala's Endosulfan Ban - The science ...
      • Patent Office publishes all 'Statements of Working...
      • SpicyIP Weekly Review (June 4th Week)
      • Rise of the Indian Big Brother
      • SpicyIP Jobs: Lawyers Collective seeks to recruit ...
      • SpicyIP Event: IPEX - 2013, Hyderabad
      • SpicyIP Announcement: Franklin Pierce Centre for I...
      • Guest Post: U.S. Supreme Court rules on the legali...
      • The trend of blocking URL's on ISP's continues in ...
      • Guest Post: The opinion of the U.S. Supreme Court ...
      • SpicyIP Tidbit Update: Thai Compulsory Licensing i...
      • Copyright Hiccup: Madras High Court allows release...
      • SpicyIP Weekly Review(June 3rd Week)
      • Indian start-up complains about unfair Google Ad-S...
      • DIPP issues notification proposing an across the b...
      • SpicyIP Tidbit: Thai Govt. plans to issue compulso...
      • SpicyIP Events: FMC-DSIR-APTDC Workshop for Identi...
      • Movie makers threatened for trademark dilution, Ka...
      • SpicyIP Event: IPEX - 2013, Hyderabad
      • The Sunitinib Saga continues: Third time’s the charm?
      • Battleground shopping: Big Pharma versus Indian Pa...
      • Decriminalizing Defamation – Are Sections 499/500 ...
      • Artists unionize and register copyright societies ...
      • Indian publisher threatens blogger with 1 billion ...
    • ►  May (32)
    • ►  April (51)
    • ►  March (66)
    • ►  February (40)
    • ►  January (49)
  • ►  2012 (131)
    • ►  December (29)
    • ►  November (42)
    • ►  October (50)
    • ►  September (10)
Powered by Blogger.